Skip to main content
. 2023 Mar 15;7(13):3225–3231. doi: 10.1182/bloodadvances.2022009323

Table 5.

Treatment-related adverse events

Adverse event
Neuropathy 28 (42%)
 PSN 9 (13%)
 PMN 4 (6%)
 Both PMN and PSN 15 (22%)
Neutropenia 20 (30%)
Thrombocytopenia 8 (12%)
Anemia 6 (9%)
Pulmonary toxicity 6 (9%)
Transaminitis 5 (7%)
Infusion reaction 4 (6%)
Nausea/vomiting 3 (4%)
Cardiotoxicity 2 (3%)
Secondary malignancy 1 (2%)